{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:28Z","timestamp":1761941908094,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vhri.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T23:59:40Z","timestamp":1639612780000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of Rituximab (Fixed Schedule vs Tailored Dose) Compared With Azathioprine Maintenance Therapy in Adults With Generalized Antineutrophil Cytoplasm Antibody-Associated Vasculitis in Colombia"],"prefix":"10.1016","volume":"28","author":[{"given":"Kateir","family":"Contreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Puche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Garc\u00eda-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Patricia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Rosselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vhri.2021.08.002_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2021.08.002_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2021.08.002_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.vhri.2021.08.002_bib4","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.vhri.2021.08.002_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.vhri.2021.08.002_bib6","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.vhri.2021.08.002_bib7","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143-1149. Erratum in:","volume":"78","author":"Charles","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.vhri.2021.08.002_bib8","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.vhri.2021.08.002_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3899\/jrheum.150376","article-title":"CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides","volume":"43","author":"McGeoc","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.vhri.2021.08.002_bib10","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. Erratum in:","volume":"76","author":"Yates","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.vhri.2021.08.002_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/rheumatology\/ket304","article-title":"A\u00a0cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand","volume":"53","author":"Mohara","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.vhri.2021.08.002_bib12","first-page":"177","article-title":"The Delphi method in rheumatology research: are we doing it right?","volume":"27","author":"Fern\u00e1ndez-\u00c1vila","year":"2020","journal-title":"Rev Colomb Reumatol"},{"key":"10.1016\/j.vhri.2021.08.002_bib13","unstructured":"Institute of Technological Evaluation in Health. Manual for the preparation of economic evaluations in health. Bogot\u00e1 D.C.: IETS; 2014. http:\/\/www.iets.org.co\/Archivos\/64\/ Manual_evaluacion_economica.pdf. Accesed July 15, 2021."},{"issue":"2","key":"10.1016\/j.vhri.2021.08.002_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2021.08.002_bib15","first-page":"137","article-title":"Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37 Suppl 117(2)","author":"Montante","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.vhri.2021.08.002_bib16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomized controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.vhri.2021.08.002_bib17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.vhri.2021.08.002_bib18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener\u2019s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.vhri.2021.08.002_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.vhri.2021.08.002_bib20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.vhri.2021.08.002_bib21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:09Z","timestamp":1761941589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"alternative-id":["S2212109921001205"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2021.08.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Rituximab (Fixed Schedule vs Tailored Dose) Compared With Azathioprine Maintenance Therapy in Adults With Generalized Antineutrophil Cytoplasm Antibody-Associated Vasculitis in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}